Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924041 | 0.91 | LTA4H (0.52) | ALDH1A1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19178207 | 0.88 | PARP1 (0.44) | ALDH1A1PARP1HRH3PARP2IDH1 | |
| SCHEMBL14846571 | 0.88 | PARP1 (0.44) | ALDH1A1PARP1HRH3PARP2IDH1 | |
| SCHEMBL24246892 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HTTSMN1; SMN2HRH3LMNA | |
| SCHEMBL4260843 | 0.84 | LMNA (0.57) | ALDH1A1PARP1HRH3LMNAPARP2 | |
| SCHEMBL21190296 | 0.83 | BCHE (0.54) | ALDH1A1SMN1; SMN2LMNABCHEFAAH | |
| SCHEMBL3605410 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL24451870 | 0.82 | PDE2A (0.47) | ALDH1A1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17465246 | 0.82 | HRH3 (0.69) | ALDH1A1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12074554 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2APARP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | ALDH1A1 921/4885HTT 1870/4885SMN1; SMN2 7/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | ALDH1A1 3955/4885HTT 4145/4885SMN1; SMN2 3453/4885 |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, VHL | ALDH1A1 2242/4885HTT 901/4885SMN1; SMN2 4032/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | ALDH1A1 921/4885HTT 1870/4885SMN1; SMN2 7/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | ALDH1A1 3912/4885HTT 4208/4885SMN1; SMN2 3653/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | ALDH1A1 3912/4885HTT 4208/4885SMN1; SMN2 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.